Loading
A phase 3 trial testing QLS31905 in pancreatic ductal adenocarcinoma, now recruiting.
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer is a phase 3 interventional study registered as NCT07079228, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Phase 3, Multi-Center, Double-blind, Randomised Study of QLS31905 Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment in Participants With Claudin (CLDN)18.2-Positive Advanced Pancreatic Cancer. Planned enrolment is 602 participants (estimated). The study started in 2025-09-08 and primary completion is expected in 2028-12. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/